Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
School of Biomedical Sciences, Kent State University, Kent, OH 44242, USA.
Int J Mol Sci. 2024 Aug 10;25(16):8731. doi: 10.3390/ijms25168731.
Type 2 diabetes mellitus (T2DM), often featuring hyperglycemia or insulin resistance, is a global health concern that is increasing in prevalence in the United States and worldwide. A common complication is metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of metabolic syndrome that is also rapidly increasing in prevalence. The majority of patients with T2DM will experience MASLD, and likewise, individuals with MASLD are at an increased risk for developing T2DM. These two disorders may act synergistically, in part due to increased lipotoxicity and inflammation within the liver, among other causes. However, the pathophysiological mechanisms by which this occurs are unclear, as is how the improvement of one disorder can ameliorate the other. This review aims to discuss the pathogenic interactions between T2D and MASLD, and will highlight novel therapeutic targets and ongoing clinical trials for the treatment of these diseases.
2 型糖尿病（T2DM）常伴有高血糖或胰岛素抵抗，是一个全球性的健康问题，在美国和全球的患病率都在上升。一种常见的并发症是代谢功能障碍相关的脂肪性肝病（MASLD），这是代谢综合征在肝脏的表现，其患病率也在迅速上升。大多数 T2DM 患者会出现 MASLD，同样，患有 MASLD 的个体发生 T2DM 的风险也会增加。这两种疾病可能会协同作用，部分原因是肝脏内的脂毒性和炎症增加等原因。然而，其发生的病理生理机制尚不清楚，改善一种疾病如何能改善另一种疾病也不清楚。本综述旨在讨论 T2D 和 MASLD 之间的发病机制相互作用，并强调治疗这些疾病的新的治疗靶点和正在进行的临床试验。
Zotero 插件
